In the glittering world of celebrity-endorsed weight loss transformations and viral before-and-after photos, a darker narrative is emerging from the shadows ...
22h
Research links weight loss medications like Ozempic and Zepbound to certain serious eye conditions.
Independence Blue Cross began limiting coverage of GLP-1 drugs on Jan. 1 to some medical conditions, but not obesity or weight loss.
Phase 2 obesity co-administration study with MC4R agonist bremelanotide plus GLP-1/GIP dual agonist tirzepatide Database lock completed Topline data readout ...
Compounded weight-loss medications, such as those promoted in the Hims & Hers commercial, aren’t approved by the Food and ...
Global Healthy Living Foundation Says Hims & Hers Health Super Bowl ad omits safety risks and side effects of its weight loss ...
Viking Therapeutics (NASDAQ: VKTX) shares exploded higher after the clinical-stage drugmaker announced successful results ...
Eli Lilly expects to read out results from a study in people with obesity and osteoarthritis of the knee in 2025.
Registered Phase-1b 12-week study investigating safety, diabetes control, and weight loss KELOWNA, BC / ACCESS Newswire / February 5, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "L ...
Trusted source of information on diabetes that includes articles, news, videos, animations, quizzes, calculators and drugs.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback